The EMBRACE Trial: Eisai Metastatic BReast cancer study Assessing physician's Choice versus E7389. A phase III open label, randomized, parallel, two-arm, multi-center study of E7389 [eribulin] versus 'treatment of physician's choice' in patients with locally recurrent, metastatic breast cancer, previously treated with at least two and a maximum of five prior chemotherapy regimens, including an anthracycline and a taxane

Trial Profile

The EMBRACE Trial: Eisai Metastatic BReast cancer study Assessing physician's Choice versus E7389. A phase III open label, randomized, parallel, two-arm, multi-center study of E7389 [eribulin] versus 'treatment of physician's choice' in patients with locally recurrent, metastatic breast cancer, previously treated with at least two and a maximum of five prior chemotherapy regimens, including an anthracycline and a taxane

Completed
Phase of Trial: Phase III

Latest Information Update: 13 May 2016

At a glance

  • Drugs Eribulin (Primary) ; Antineoplastics; Aromatase inhibitors
  • Indications Advanced breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms EMBRACE
  • Sponsors Eisai Co Ltd
  • Most Recent Events

    • 13 May 2016 Pooled subgroup analysis results of two phase III trials (assessing efficacy of eribulin in various subgroups; studies 301 and 305) published in the Annals of Oncology
    • 12 May 2016 New data published in the British Journal of Cancer, as per Eisai media release.
    • 11 May 2016 Results published in Eisai media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top